Monday, 2 February 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 02 February 2026
News

New cancer drug targets Australia

Posted 28 January 2026 PM

Akamis Bio’s lead oncolytic immunotherapy NG-350A could soon reach Australia, with steps already in motion for Novotech to conduct a clinical trial in patients with locally advanced rectal cancer.

The Gene Technology Regulator received a license application from Novotech to conduct the study in September. Comments are now being sought on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) that has been prepared by the Office of the Gene Technology Regulator (OGTR).

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (16)

Access & Reimbursement (1)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (5)

Other (18)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.